CMB International Leads $100M Series B Round Into US Biopharmaceutical Firm

U.S. biopharmaceutical company Apollomics, Inc., has raised US$100 million in a series B financing round, led by CMB International (CMBI), a subsidiary of China Merchants Bank. The round was also participated in by existing series A round investor, OrbiMed Asia, according to an announcement today.  Several new investors, including Guangzhou Yue Min Investment, South China […]

CMB International Leads $100M Series B Round Into US Biopharmaceutical Firm appeared first on China Money Network.

Read the original article: China Money Network